Suppr超能文献

采用新型两性霉素 B 和氟康唑负载双重递药系统对抗隐球菌病的联合治疗的增效作用。

Additive potential of combination therapy against cryptococcosis employing a novel amphotericin B and fluconazole loaded dual delivery system.

机构信息

Pharmaceutical Biotechnology Laboratory, Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

Pharmaceutical Biotechnology Laboratory, Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.

出版信息

Eur J Pharm Sci. 2018 Jul 1;119:171-178. doi: 10.1016/j.ejps.2018.04.015. Epub 2018 Apr 11.

Abstract

Cryptococcus neoformans is one of the most lethal fungi causing mortality across the globe. Immuno-competent patients and patients taking immuno-suppressive medications are extremely susceptible to its infection. For effective removal of cryptococcal burden, there is an urgent need for new forms of therapy. In the present study, we have explored the potential effects of amphotericin B (AMB) and fluconazole (FLC) in combination, against cryptococcosis in Swiss albino mice. To enhance the therapeutic potential of the tested drugs, they were entrapped into fibrin microspheres; a dual delivery vehicle comprising of poly-lactide co-glycolide (PLGA) microsphere that was additionally encapsulated into the fibrin cross-linked plasma bead. Dynamics of fibrin microspheres included survival and fungal burden in lung, liver and spleen of treated mice. While each drug was effective in combination or alone, prominent additive potential of AMB and FLC were clearly observed when used in fibrin microsphere. Significant reduction in fungal burden and increase in survival rate of AMB + FLC-fibrin microspheres treated mice shows an extensive accessibility of both tested drugs without any side-effects. A full potential of two-drug combination encapsulated in fibrin microspheres proposes an effective approach of safe delivery to the target site in their intact form and decrease the drug associated toxicities.

摘要

新型隐球菌是全球致死率最高的真菌之一。免疫功能正常的患者和服用免疫抑制剂的患者极易感染这种真菌。为了有效清除隐球菌负荷,我们迫切需要新的治疗方法。在本研究中,我们探索了两性霉素 B (AMB) 和氟康唑 (FLC) 联合应用对瑞士白化病小鼠隐球菌病的潜在影响。为了提高测试药物的治疗潜力,我们将它们包封到纤维蛋白微球中;这是一种双重递药载体,由聚乳酸-共-羟基乙酸 (PLGA) 微球组成,此外还包封到纤维蛋白交联的血浆珠中。纤维蛋白微球的动力学包括治疗小鼠肺、肝和脾中的存活和真菌负荷。虽然每种药物单独或联合使用都有效,但当在纤维蛋白微球中使用时,AMB 和 FLC 的明显相加潜力是显而易见的。AMB+FLC-纤维蛋白微球治疗的小鼠的真菌负荷显著减少和存活率显著提高表明,两种测试药物都具有广泛的可及性,而没有任何副作用。封装在纤维蛋白微球中的两药联合的全部潜力提出了一种有效的方法,以安全地将药物递送到目标部位,并减少与药物相关的毒性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验